Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Zeitschrift für Rheumatologie 56 (1997), S. 276-286 
    ISSN: 0340-1855
    Keywords: Schlüsselwörter HCV-Infektion ; chronische Polyarthritis ; HCV-assoziierte Arthritis ; Kryoglobuline ; Sicca-Syndrom ; Key words HCV-Infection ; Rheumatoid Arthritis ; HCV-associated Arthritis ; Cryoglobulins ; Sicca-syndrome
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary HCV-infection is an important infectious disease in rheumatology. It is the cause of mixed cryoglobulinemia and other rheumatic manifestations develop frequently during HCV-infection. These comprise: Sicca-syndrome, thromboembolic events associated with anti-cardiolipin antibodies and fibromyalgia. Also associated with HCV-infection is a non-erosive polyarthritis. This synovitis often fulfills the ACR-criteria for rheumatoid arthritis, but the disease course is different with frequent remissions and non-erosive joint involvement. The following autoantibodies are associated with HCV-infection: Cryoglobulins, rheumatoid factor, anti-nuclear antibodies (ANA), anti-smooth muscle antibodies (SMA), anti-phospholipid-antibodies and anti-thyroid-antibodies. In HCV-associated sicca-syndrom, antibodies against Ro (SSA) and La (SSB) are not detected. The course of HCV-infection is often occult, without elevation of liver enzymes. We summarize the clinical and serological signs and symptoms when HCV-infection should be suspected and when HCV-testing should be performed in a rheumatological setting. The identification of HCV-infection in rheumatic patients is important to minimize the risk of aggravating hepatitis by prescription of hepatotoxic drugs and because of the availability of α-interferon as a potential virus eradicating agent.
    Notes: Zusammenfassung Die Hepatitis C-Virus (HCV)-Infektion ist eine für die rheumatologische Praxis relevante Infektionserkrankung. Sie ist Ursache der gemischten Kryoglobulinämie. Zusätzlich entwickeln viele HCV-Patienten rheumatische Begleitmanifestationen. Rheumatologisch relevante Manifestationen sind: Sicca-Syndrom, thromboembolische Ereignisse bei Vorliegen von Anti-Kardiolipin-Antikörpern und Fibromyalgiesyndrom. Ebenfalls HCV-assoziiert, ist eine zumeist seropositive polyartikuläre Arthritis. Diese erfüllt die klinischen Kriterien der chronischen Polyarthritis, nimmt aber einen anderen Verlauf. Remissionen werden häufig beobachtet, erosive Verläufe sind die Ausnahme. Folgende Autoantikörper sind mit der HCV-Infektion assoziiert: Kryoglobuline, Rheumafaktoren, Anti-Nukleäre-Antikörper (ANA), Antikörper gegen glatte Muskulatur (SMA), Anti-Phospholipid-Antikörper, Schilddrüsenautoantikörper. Antikörper gegen Ro und La sind bei der HCV-Infektion nicht nachweisbar. Da die Leberentzündung zumeist okkult verläuft, ist auch bei normalen Lebertransaminasen eine HCV-Infektion nicht ausgeschlossen und die Indikation zur HCV-Testung gegeben, wenn bestimmte serologische und klinische Hinweise vorliegen. Bei positivem HCV-Nachweis sollte auf hepatotoxische Medikamente verzichtet und die Möglichkeit einer viruseradizierenden Therapie mit α-Inferferon erwogen werden.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1434-9949
    Keywords: Auranofin ; Gold Treatment ; Disease Modifying Drugs ; Rheumatoid Arthritis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1434-9949
    Keywords: Auranofin ; Gold Sodium Thiomalate ; Rheumatoid Arthritis ; Treatment ; Long-term Treatment ; Gold Salts
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary One hundred twenty-one patients with active RA were randomly assigned to receive 6 mg auranofin (AF)/day (60 patients) or 50 mg gold sodium thiomamate (GST)/week (62 patients) in a double-blind fashion. There were no intergroup differences with respect to sex, age, duration (median 2 years), stage and activity of the disease. In the case of “striking improvement” after 24 weeks a dose reduction to 50 mg GST/month or 4 mg AF/day was allowed and carried out in all GST patients and no AF patient. The serum gold levels were 5 times higher with weekly GST, they approached those of the AF group with monthly GST injections. The clinical parameters — number of swollen joints, activity index, articular index, grip strength, ESR — improved significantly in both groups, but grip strength, articular index and ESR improved more pronounced in the GST group. The X-ray progression (hands and forefeet) was significantly greater in the AF group. Fourthy eight AF patients (80%) and 39 GST patients (36%) completed the first year. Thereafter the study was continued as an open study but the patients were allowed to switch from GST to AF. After the first and second year 14/7 GST patients switched to AF. The second/third year was completed by 37/22 AF pat. (62%/37%) and by 15/8 GST pat. (24%/13%). Skin reactions were more common with GST (41.9%/26.7%), diarrhoea was more common with AF (36.7%/19.4%), proteinuria occurred in 10% in both groups, leucopenia and thrombocytopenia were rare in both groups (1.7%). The withdrawal rate due to adverse events was 10%/26% in the AF/GST group during the first year (p〈0.05) and 25%/32% over the three year period (n.s.). Conclusion Both AF and GST are effective in the long-term treatment of RA, but GST is more so in radiological progression and ESR.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...